Kauli R, Pertzelan A, Prager-Lewin R, Grünebaum M, Laron Z
Arch Dis Child. 1976 Mar;51(3):202-8. doi: 10.1136/adc.51.3.202.
Twenty-nine children (23 girls, 6 boys) with precocious puberty were treated with cyproterone acetate for various periods of time ranging from 6 months to 3 years 4 months. They received an oral dose ranging from 70-150 mg/m2 per day, or an intramuscular depot injection once a fortnight or once a month at a dose ranging from 107-230 mg/m2. Both forms of therapy were found to suppress the signs of sexual maturation, but the oral form proved to be superior. Only the younger patients with a bone age under 11 years showed a beneficial effect upon linear growth and bone maturation. No side effects were noted, but additional advantageous effects upon behaviour and sociability were. It is concluded that at present cyproterone acetate by mouth is the drug of choice in the treatment of precocious puberty. The treatment should be initiated as early as possible to attain maximum benefit.
29名性早熟儿童（23名女孩，6名男孩）接受了醋酸环丙孕酮治疗，治疗时间从6个月至3年4个月不等。他们每日口服剂量为70 - 150毫克/平方米，或每两周或每月进行一次肌肉注射长效针剂，剂量为107 - 230毫克/平方米。两种治疗方式均能抑制性成熟迹象，但口服方式效果更佳。只有骨龄低于11岁的较年幼患者在身高线性增长和骨骼成熟方面显示出有益效果。未观察到副作用，但在行为和社交能力方面有额外的有利影响。结论是，目前口服醋酸环丙孕酮是治疗性早熟的首选药物。治疗应尽早开始以获得最大益处。
